Nathan K. LeBrasseur

Oct 25, 2024 | seniorsguide.com | Brian Marsh |Nathan K. LeBrasseur |Mackenzie Burgess

Senior Health 10/25/2024 | By Kristen N. Smith Probiotics are live microorganisms that provide health benefits when consumed in adequate amounts. Found in fermented foods and supplements, these beneficial bacteria are particularly renowned for their role in promoting gut health, enhancing immune function, and supporting overall well-being. We look closer at the benefits of probiotics. Gut health and digestion Probiotics are most commonly associated with improved gut health.

Oct 22, 2024 | seniorsguide.com | Nathan K. LeBrasseur |Annie Tobey |Mackenzie Burgess |Howard LeWine

Senior Health 10/22/2024 | By Nathan LeBrasseur Is there a difference in lifespan vs. healthspan? Yes, says Nathan LaBrasseur of Director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic, and both can be improved. DEAR MAYO CLINIC: I’ve been hearing a lot lately about healthspan versus lifespan when it comes to aging. What do they each mean? And what is the difference? ANSWER: We get a lot of questions about what distinguishes between lifespan and healthspan.

Oct 17, 2024 | transylvaniatimes.com | Nathan K. LeBrasseur

Dear Mayo Clinic: I’ve been hearing a lot lately about healthspan versus lifespan when it comes to aging. What do they each mean and what is the difference? We get a lot of questions about what distinguishes between lifespan and healthspan. The simplest answer is to paraphrase a quote from President John F.

Sep 15, 2024 | nature.com | Jesse R. Poganik |Daniel Belsky |Joe LaCroix |Alan Cohen |Steven R. Cummings |Luigi Ferrucci | +15 more

AbstractBiomarkers of aging (BOA) are quantitative parameters that predict biological age and ideally its changes in response to interventions. In recent years, many promising molecular and omic BOA have emerged with an enormous potential for translational geroscience and improving healthspan. However, clinical translation remains limited, in part due to the gap between preclinical research and the application of BOA in clinical research and other translational settings.

Jul 2, 2024 | nature.com | Joshua N Farr |Jad G. Sfeir |Dominik Saul |Kai Yu |Tamara Tchkonia |Nathan K. LeBrasseur | +2 more

AbstractPreclinical evidence demonstrates that senescent cells accumulate with aging and that senolytics delay multiple age-related morbidities, including bone loss. Thus, we conducted a phase 2 randomized controlled trial of intermittent administration of the senolytic combination dasatinib plus quercetin (D + Q) in postmenopausal women (n = 60 participants).